STOCK TITAN

Innovent Biologics Inc - IVBIY STOCK NEWS

Welcome to our dedicated news page for Innovent Biologics (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innovent Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innovent Biologics's position in the market.

Rhea-AI Summary
Innovent Biologics and IASO Bio announce updated long-term follow-up data on BMCA CAR-T therapy for multiple myeloma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Innovent Biologics announces 2023 interim results and major company updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Innovent Biologics, Inc. announces that China's National Medical Products Administration has approved SINTBILO®, a PCSK9 inhibitor, for the treatment of hypercholesterolemia and mixed dyslipidemia. This is Innovent's first drug in the cardiovascular field and its tenth product in its commercial portfolio. The approval is based on three Phase 3 clinical trials, and SINTBILO® has shown significant and sustained LDL-C reduction. The approved dosing regimens provide more individualized choices for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Innovent Biologics, Inc. announced that the preclinical results of IBI363 were published in Nature Cancer. The results showed that α-biased IL-2, a component of IBI363, demonstrated superior anti-tumor efficacy and lower toxicity compared to 'not-α' IL-2. IBI363, a PD-1/IL-2 bispecific antibody fusion protein, is currently in Phase 1 studies to evaluate its safety and preliminary antitumor efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
-
-
-
Rhea-AI Summary
Innovent Biologics, Inc. announced Phase 1b clinical data of IBI110 in the first-line treatment of gastric cancer and hepatocellular carcinoma. In the gastric cancer study, 15 patients achieved a partial response, with an overall response rate of 88.2%. The median duration of response was 10.6 months, and the median progression-free survival was 12.9 months. In the hepatocellular carcinoma study, the objective response rate was 29.6%, and the disease control rate was 85.2%. The median progression-free survival was 9.9 months. Both studies showed manageable safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Innovent Biologics Inc

OTC:IVBIY

IVBIY Rankings

IVBIY Stock Data

7.84B
1.38B
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
China (Mainland)
Suzhou